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Asthma is a syndrome characterized by 
intermittent attacks, often nocturnal, of 
breathlessness, wheezing, and cough. 
Onset of the disease is most common 
during childhood, when it can usually 
be controlled with inhaled medications. 
Asthma runs a variable natural history, 
and as many as one in four patients may 
continue to have symptoms that persist 
or recur in adulthood. The childhood dis-
ease is often associated with other aller-
gic disorders, such as atopic dermatitis 
(eczema) and seasonal rhinitis (hayfever). 
The latter manifestations can precede 
the recognition of full-blown asthma, 
a processive sequence denoted the 
“atopic march.” Patients with persistent 
disease into adulthood, or those who 
have onset in adulthood, are more likely 
to include subgroups with more frequent 
and severe episodes that require intensi-
fication of therapy. In general, however, 
the severity of the disease is usually 
established at or near the time of onset.
A breakthrough in the understanding of 
asthma pathogenesis was made with the 
recognition that chronic inflammation of 
the conducting airways characterizes the 
disease, even during asymptomatic peri-
ods. Inflammation includes the presence 
of CD4 T helper 2 (Th2) cells and Th2-
associated cytokines, as well as eosino-
phils, a finding that has greatly informed 
experimental animal studies seeking to 
understand the initiation and mainte-
nance of allergic immunity (Robinson 
et al., 1992). More recent findings have 
suggested that IL-17-associated neu-
trophil inflammation of the airways and 
even “pauci-granulocytic” subtypes with 
minimal inflammatory cell infiltrates can 
occur (Wenzel, 2006). Whether alternative 
forms of inflammation represent distinct 
subtypes of the disease or heterogene-
ity in the response to currently available 
therapeutics, or both, is unknown. Per-
sistent inflammation, possibly fueled by 
immune responses to repeated inhala-
tions of environmental allergens, such as 
pollens, grasses, animal danders, molds, 
and excreta from urban-dwelling insects 
(particularly dust mites and cockroaches), 
results in compensatory structural airway 
alterations. These include epithelial mucus 
metaplasia, smooth muscle hypertrophy, 
and enhanced deposition of subepithe-
lial matrix glycoproteins. These changes, 
collectively termed “airway remodeling,” 
are thought to lead to the persistent, 
poorly reversible airflow limitations and 
airway hyper-responsiveness found in 
some patients with chronic asthma. Air-
way hyper-responsiveness is revealed by 
aerosolized agonist drugs, such as meth-
acholine, that induce smooth muscle con-
traction, by respiratory irritants, including 
pollutants (e.g., sulfur dioxide, diesel fuel 
particles), or by recurrent respiratory virus 
infections, such as those caused by rhi-
noviruses or respiratory syncytial viruses. 
Despite many advances, it is clear that no 
animal model completely simulates the 
human disease. More access to human 
tissues will be required to gain a deeper 
understanding of the natural history, 
breadth, and pathogenesis of asthma.
Scope of the Problem
Asthma and allergic inflammation, 
including food allergies, have increased 
over the past 50 years to become the 
most prevalent chronic illnesses of 
childhood in developed countries. The 
estimated worldwide prevalence of 
asthma is 300 million persons. In the 
United States, childhood asthma preva-
lence more than doubled between 1980 
and the mid-1990s, with 2007 estimates 
projecting 16.2 million adults and 6.7 mil-
lion children with the disease, over 8% 
of the population (Moorman et al., 2007). 
Although mortality is infrequent, asthma 
patients drive extensive use of the health 
care system, accounting for approxi-
mately 10 million office visits, 400,000 
hospitalizations, and 200,000 emer-
gency room visits; in some communities, 
one in four emergency room patients are 
seen for asthma. Annual economic costs 
approach $20 billion in the United States 
alone. Over half of patients with asthma 
have additional allergic diseases, includ-
ing food allergies. The latter has reached 
awareness levels such that peanut butter 
has been essentially banned from grade 
schools in many metropolitan areas of 
the United States.
The increase in allergic diseases over 
relatively short time periods implicates 
environmental factors as overwhelming 
determinants of disease risk. Genetic pre-
disposition to asthma is clear, however, 
with family and twin studies suggesting 
hereditary contributions approaching 
60%. Genome-wide studies of asthma in 
carefully phenotyped populations remain 
few and, similar to other chronic complex 
human diseases, suggest relatively small 
contributions by many loci, few of which 
have been rigorously quantified (Rog-
ers et al., 2009). Posited genome-envi-
ronment interactions, as proposed for 
most complex human diseases, are only 
vaguely defined. Genetic disparities that 
drive ethnic differences in asthma risk, 
severity, or drug responsiveness also 
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Studies of the initiation and maintenance of asthma and allergic inflammation implicate dysregu-
lated interactions between mucosal epithelia and innate immune cells as the underlying cause of 
these disorders. The similarities of these responses with mucosal responses to parasitic intes-
tinal worms may reveal pathways relevant to the perplexing rise of these chronic inflammatory 
disorders.
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obscure analysis (Burchard et al., 2003). 
Replication against larger cohorts of 
well-defined populations will be needed. 
Intriguing links with genes involved in the 
pathway for the terminal differentiation 
of keratinocytes into barrier cells secret-
ing the protein-lipid matrix that regulates 
skin permeability have suggested a con-
nection with epithelial barrier dysfunc-
tion. Common loss-of-function muta-
tions in filaggrin, a cytoskeletal structural 
protein in keratinocytes, present in up 
to 10% of Western Europeans and their 
descendants have been associated with 
severe atopic dermatitis and, in some 
studies, with risk for asthma (Muller et 
al., 2009). Loss of barrier function may 
establish breaches for allergen entry and 
priming (Fallon et al., 2009) and/or lead 
to changes in the commensal microbial 
flora that alter the homeostatic regula-
tion of immunity in ways that predispose 
to allergy, perhaps mediated by elabora-
tion of the epithelial cell cytokine thymic 
stromal lymphopoietin (TSLP; Demehri 
et al., 2009). Epidemiologic studies have 
repeatedly identified more severe viral 
upper respiratory infections, most com-
monly rhinoviruses, early in life as a major 
risk, particularly in families with a history 
of atopy. An urbanized lifestyle in early 
life also increases risk, suggesting that 
post-natal exposure to indoor antigens 
or urban pollutants affects the quality 
of subsequent mucosal immunity. Alter-
natively, loss of exposure to microbes 
associated with rural environments may 
shape the infant immune system.
Whatever underlies the rising preva-
lence of asthma, it is recognized that 
some patients, although the exact pro-
portion is unknown, progress to irre-
versible lung changes characterized by 
the increased subepithelial fibrosis and 
structural hyperplasia of airway remod-
eling. When severe, these patients can 
overlap the pathologic spectrum of 
patients with chronic bronchitis. The 
impact of primary and secondary smok-
ing exposure has complicated analysis, 
although cases can occur in nonsmok-
ers. Animal models have been very 
informative in increasing understand-
ing of asthma, but these are imperfect, 
and lack of access to patient tissues has 
hampered the ability to delineate fully 
the natural history and full spectrum of 
human disease.
Figure 1. Pathways of Allergic Immunity
Initiation of allergic immunity is mediated through interactions of allergens with epithelia that result in 
release of the cytokines thymic stromal lymphopoietin (TSLP), IL-33, and IL-25. TSLP mediates migration 
of dendritic cells (DCs) and their maturation, which primes the IL-4 competency of T helper (Th) cells. 
These competent Th cells move into follicular areas of lymph nodes and mature into IL-4-secreting TFH 
cells. They mediate isotype switching in B cells in the germinal center reaction in lymph nodes. The B 
cells then produce IgE antibody (and IgG1 in the mouse). IgE, in turn, binds to mast cells and basophils, 
extending their survival and facilitating allergen-specific activation of these cells. IL-33 promotes IL-4 re-
lease from basophils, and IL-33 and IL-25 promote IL-13 and IL-5 release from IL25R+ natural helper cells 
in tissues (these cells also release IL-6, which supports B cell maturation and impairs T regulatory cells). 
IL25R+ natural helper cells and basophils together produce IL-4, IL-5, and IL-13, which promote terminal 
differentiation and/or recruitment of T helper 2 (Th2) cells to tissues, as well as alternative activation of 
macrophages (AAMφ) and eosinophil recruitment. These effects are greatly augmented by activation of 
tissue Th2 cells, which contribute a diverse set of cytokines that feed back to facilitate the survival and 
activation of innate immune cells and the effects of Th2-associated cytokines on epithelia, smooth mus-
cle, and the stromal matrix. Memory T and B cells are generated that can facilitate more rapid responses 
to repeated stimulation, particularly if the regulatory T cell response is impaired (not shown).
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Pathogenesis: Current 
Status
Asthma and food allergies 
are initiated at mucosal sur-
faces where environmental 
allergens contact epithelia. 
The physical properties that 
endow environmentally wide-
spread entities with allergenic 
properties are of much inter-
est but, in asthma, at least 
minimally involve the capacity 
to be sustained in aerosolized 
forms that reach conducting 
airways and evade muco-
ciliary clearance. Allergens 
may share properties such 
as stability, protease activity, 
or molecular mimicry, which 
endows them with the capac-
ity to penetrate mucus and 
epithelial barriers and induce 
cytokine release by engag-
ing innate pattern recognition 
receptors on epithelia and 
resident lung myeloid cells, 
including macrophages, den-
dritic cells, and mast cells. 
Natural allergens are typically complex 
biological mixtures of constituents that 
share many individual attributes, a fea-
ture infrequently addressed in experi-
mental models. Airway inflammation is 
sustained from these initial encounters 
through the interactions between epi-
thelia of the airways and recruited anti-
gen-processing cells, likely monocyte-
derived dendritic cells, although recent 
studies suggest that basophils may 
subserve this function in allergic inflam-
mation in some situations. In this way, 
adaptive immunity is engaged through 
the development of antigen-specific 
memory T cells and antibody-secret-
ing plasma cells, thus establishing the 
potential for chronicity upon repeated 
exposures to allergens.
The subsequent pathways are based 
on an amalgamation of mouse studies, 
often in the setting of overexpression or 
deletion of various genes, and human 
studies based largely on in situ analy-
sis and studies of isolated cells and cell 
lines. Differences in cells, receptors, and 
anatomy of the airways between the spe-
cies suggest caveats in creating a unify-
ing hypothesis of current understanding. 
Of necessity oversimplified, the reader 
is referred to recent reviews (Barrett and 
Austen, 2009; Lambrecht and Hammad, 
2009; Saenz et al., 2008). Briefly, current 
models envision the release of epithelial 
cytokines, particularly IL-25, IL-33, and 
TSLP, and CC family chemokines as 
proximal events important in initiating 
allergic inflammation (Figure 1). Although 
few studies are available, IL-25, IL-33, 
and TSLP can be elicited from epithelia 
when activated by allergenic stimuli or by 
helminth parasitic worms and can induce 
IL-13-dependent allergic inflammation 
when administered individually to mice 
or when overexpressed as transgenes. 
In the lung, TSLP may be released from 
other sources as well, as epithelial pro-
duction at this site is lower than in skin 
and bowel. These cytokines also target 
resident hematopoietic cells to induce 
the influx of inflammatory cells from the 
circulation and the activation and mobi-
lization of dendritic cells. Although all 
of these cytokines can target multiple 
cell types, IL-33 potently activates mast 
cells to secrete vasoactive amines, lipid 
mediators, chemokines, and cytokines 
and as such may contribute to anaphy-
laxis (Pushparaj et al., 2009). Basophils, 
initially fewer in number in parenchymal 
tissues, are also activated by 
IL-33 to secrete cytokines, 
particularly IL-4. IL-25 and 
IL-33 potently activate IL-25R+ 
lymphoid cells in tissues that 
remain incompletely charac-
terized (Fort et al., 2001; Moro 
et al., 2009). When activated, 
these lymphoid cells respond 
by producing the key cytok-
ines IL-5 and IL-13. IL-5 medi-
ates the survival of eosino-
phils, whereas IL-13 mediates 
the induction of chemokines, 
the differentiation of mucus-
secreting goblet cells, a pro-
fibrogenic stromal environ-
ment, alternative macrophage 
activation, and smooth mus-
cle alterations that contribute 
to enhanced airway hyper-
responsiveness. IL-4, which 
shares use of the type II IL-4 
receptor with IL-13, contrib-
utes to these functions of 
IL-13, making this shared 
receptor an attractive phar-
maceutical target. TSLP tar-
gets dendritic cells and mediates mobi-
lization, activation, and induction of the 
TNF superfamily member OX40L. In both 
mouse and human studies, OX40L-pos-
itive dendritic cells activate naive CD4 T 
cells to an IL-4-competent state, consis-
tent with an important priming step in 
Th2 cell differentiation.
Once activated, IL-4-competent T 
cells in lymph nodes migrate to B cell 
zones and differentiate into T follicular 
helper (TFH) cells or exit into the drain-
ing lymph and thence the circulation to 
complete maturation as Th2 cells (Figure 
1). IL-4-secreting TFH cells in parafolli-
cular B cell areas mediate IgE switching 
and conjugate with B cells to drive IgG1 
(and possibly IgG4 in human) switching 
and affinity maturation within germinal 
centers in lymph nodes (Reinhardt et 
al., 2009). The understanding of TFH cells 
has been confusing due to the inabil-
ity to distinguish these cells by surface 
phenotype, which is shared among most 
activated T cells in the lymph node. Most 
lymph node IL-4-secreting cells during 
allergic immunity are actually TFH cells 
that mediate B cell help and not Th2 
cells, which exit the lymph node and go 
to peripheral sites of inflammation. In 
Figure 2. Asthma and Helminth Infection
The loss of universal helminth infections that occurred during human evolution 
may have altered the numbers or types of bacterial and fungal commensals 
and thus may have affected normal mucosal tissue homeostasis. In suscep-
tible or highly exposed individuals, such alterations might alter the balance 
between immunotolerance, immunosurveillance, and nutrient extraction. This 
imbalance may contribute to the appearance of inflammatory systemic dys-
regulation at mucosal surfaces, resulting in increases in asthma and allergic 
diseases, particularly in the setting of environmental changes that have in-
creased exposure to indoor allergens and pollutants, and even in increases in 
obesity, which can be a risk factor for severe asthma.
780 Cell 140, March 19, 2010 ©2010 Elsevier Inc.
tissues, effector Th2 cells augment the 
survival of eosinophils and basophils by 
secretion of IL-5 and IL-3, respectively, 
facilitate mast cell survival via IL-9, and 
contribute antigen-specific elaboration 
of IL-4 and IL-13 required for epithelial 
and smooth muscle manifestations of the 
disease. Eosinophils, when sustained, 
mediate tissue remodeling and fibrosis. 
Macrophages assume an alternatively 
activated state in the setting of IL-4 
and IL-13 stimulation and secrete pro-
teases and enzymes involved in matrix 
remodeling; these cells also participate 
in restraining tissue inflammation. Many 
manifestations of the response resemble 
wound healing and likely target resolu-
tion of the mucosal irritation. Over time, 
allergen-specific IgE (and, in the mouse, 
IgG1) antibodies occupy the high-affinity 
IgE Fc immunoglobulin receptor, FcεRI, 
expressed on mast cells and basophils 
(and, in the mouse, the respective IgG1-
binding FcγRIII on these cells as well) 
to provide alternative mechanisms for 
cell activation by antibody crosslinking. 
With repeated allergen exposure, FcεRI 
activation leads to the rapid production 
of vasoactive amines and lipid media-
tors that underlie the acute fall in respi-
ratory function after allergen challenge, 
while also driving the elaboration of 
cytokines, chemokines, and lipid media-
tors that regulate the delayed phase of 
the inflammatory process amplified by 
recruited cells. A common emergent 
theme is the role of adaptive immunity in 
providing cytokines and growth factors 
that sustain the recruitment, retention, 
and extended life span of a select group 
of myeloid cells, including eosinophils, 
basophils, and mast cells, in involved 
tissues. Occupancy of FcεRI by IgE can 
itself enhance the survival of mast cells 
and basophils, and serum IgE levels in 
humans correlate with FcεRI expression 
levels on dendritic cells, where, unlike in 
the mouse, components of the FcεRI are 
constitutively present on additional types 
of hematopoietic cells (Kraft and Kinet, 
2007). Even relatively rare cell types, 
such as basophils, are increased in tis-
sues from cases of fatal asthma (Kepley 
et al., 2001).
Control of inflammation by regula-
tory T cells (Treg) may also be compro-
mised in asthma, although the precise 
pathways remain unclear. TGF-β and 
IL-10 have been implicated in the reso-
lution of allergic inflammation by Treg, 
but dysregulated expression of these 
cytokines has been connected with pro-
gressive fibrosis and with a diminished 
capacity to restrain respiratory viruses, 
respectively. Further study of the natu-
ral history of Treg and their specificity 
in allergic lung inflammation is needed 
(Lloyd and Hawrylowicz, 2009). With 
repeated allergen exposure, eosinophil 
and basophil infiltration become sus-
tained, the mast cell pool enlarges, the 
epithelia undergo enhanced goblet cell 
differentiation with copious mucus pro-
duction, thickening of the basal lamina 
reticularis is apparent, and increases in 
smooth muscle mass occur. The result 
is hyper-responsiveness to common air-
way irritants. Although much insight has 
been gained in understanding the patho-
genesis of asthma associated with Th2 
cells and allergic pathology, very little is 
understood regarding the mechanisms 
that sustain airway inflammation among 
patients with neutrophilic or “pauci-
granulocytic” presentations that make 
up a substantial number of adult-onset 
cases of asthma.
New Directions and Needs
Common environmental allergens are 
complex mixtures of bioactive entities. 
House dust mite allergens that elicit IgE 
reactivity include a papain-like cysteine 
protease; a lipid-binding MD-2 molecular 
mimetic capable of augmenting TLR4 sig-
naling (Trompette et al., 2009); trypsin-like, 
chymotrypsin-like, and serine proteases; 
fatty acid- and lipid-binding proteins; chi-
tinases; and at least ten other proteins 
(Thomas et al., 2002). Chitin and a variety 
of polymeric glycans are also present in 
mite and cockroach fecal pellets. Cock-
roach allergens are similarly diverse and 
include active proteases and lipid-binding 
proteins involved in food digestion that are 
secreted in the fecal pellets. Fungi, a highly 
diverse spectrum of organisms, can con-
tribute up to 10% of the particulate mass 
in air of sufficient size to be inhaled into 
the terminal airways and alveoli (Frohlich-
Nowoisky et al., 2009). Fungi contain cell 
wall chitin and β-glucans that potently 
elicit eosinophil and neutrophil tissue infil-
tration in experimental models and also 
secrete proteases implicated in allergic 
lung immunity (Porter et al., 2009).
Chitinases and β-glucanases are 
present in plants and are induced in 
edible fruits and berries as part of evolu-
tionarily ancient components of defense 
against invasive chitin-bearing fungi and 
insects. Like chitinases in insect excreta, 
these plant-derived proteins, together 
with a number of lipid-binding proteins, 
are common targets of IgE reactivity in 
atopic individuals. Cross-reactivity of IgE 
may occur among these shared group 
responses. Such cross-reactivity with 
chitin- and β-glucan-binding domain-
like structures in natural latex rubber 
has been proposed to contribute to the 
prevalence of “latex-fruit syndrome”; 
similar cross-reactivity may underlie the 
emergence of “pollen-food allergy syn-
drome.” Immunologists are only begin-
ning to explore these complex antigen 
mixtures in experimental models of aller-
gic lung disease, which, in humans, is 
sustained by “cocktails” of diverse natu-
ral substances that intersect multiple 
innate immune pathways and contribute 
to allergenic priming and inflammation.
Cell wall β-glucans in fungi are potent 
stimuli of dectin C-type lectin receptors 
on dendritic cells, macrophages, and 
neutrophils and initiate IL-17-driven neu-
trophilic infiltration that may be relevant 
to the understanding of inflammatory 
subsets of asthma (Goodridge et al., 
2009). Chitin, an insoluble polymer of 
N-acetyl-β-D-glucosamine, is a struc-
tural element shared by fungi, crustacea, 
helminthes, and insects and constitutes, 
after cellulose, the most widespread 
natural biopolymer. When administered 
to the airways of mice, chitin induces a 
leukotriene-mediated infiltrate of eosino-
phils and basophils and drives alternative 
macrophage activation in both resident 
and recruited macrophages (Reese et al., 
2007). A conserved epithelial and mac-
rophage chitinase, AMCase, is rapidly 
induced by a Stat6-dependent pathway 
and degrades chitin, thus solubilizing the 
particulate structure. Chitin is a compo-
nent of the fungal cell wall and a constitu-
ent of the insect peritrophic matrix (PM). 
The PM is a complex network of chitin, 
chitin-binding proteins, glycoproteins, 
and glycans that encloses the food bolus 
with a mix of intestinal digestive enzymes 
(Hegedus et al., 2009). Spatially com-
partmentalizing the digestive process in 
the insect, the PM is ultimately excreted 
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as fecal particles enveloping the diges-
tive enzymes, including the allergenic 
proteases and lipid-binding proteins. 
Further work is necessary to establish 
whether environmental chitin from molds 
and insect excreta contributes to their 
sensitizing capacity, and whether such 
associations contribute to links between 
asthma risk and prevalent human vari-
ants of AMCase (Seibold et al., 2009). 
Intriguingly, variants of the chitin-binding 
chi-lectin, YKL-40, have also been asso-
ciated with asthma (Ober et al., 2008).
Several recent reports have used 
approaches to isolate MHC class II 
expression to basophils in experimen-
tal mouse systems involving proteases, 
helminths, IgE-mediated immunity, and 
airways challenge to suggest a requisite 
role for basophils as antigen-processing 
and -presenting cells in allergic immu-
nity (Niu et al., 2009; Perrigoue et al., 
2009; Sokol et al., 2009; Yoshimoto et 
al., 2009). Together, the findings in mul-
tiple systems using creative reagents 
demand further scrutiny of the possi-
bility, although caution will be required 
before divesting dendritic cells of their 
role in Th2-associated lung immunity. 
Mechanisms for purifying and identify-
ing basophils, and for maintaining their 
viability, remain imperfect, and reliance 
on FcεRI antibodies for basophil dele-
tion and detection may be problem-
atic if mouse dendritic cells in allergic 
inflammatory states can be induced to 
express this receptor (Grayson et al., 
2007). Novel reagents that direct MHC 
class II to CD11c-expressing cells were 
used to demonstrate the lack of need for 
classical dendritic cells but do not reca-
pitulate wild-type expression of MHC 
class II on dendritic cells, particularly 
on migratory dendritic cells required for 
the efficient induction of effector immu-
nity (Allenspach et al., 2008). Further, 
CD11c is expressed on other cells during 
allergic inflammation, including eosino-
phils (Voehringer et al., 2004). Indeed, 
all myeloid cells, including neutrophils, 
basophils, eosinophils, mast cells, and 
monocyte/macrophages can be induced 
to express MHC class II and some have 
been linked with antigen presentation 
(Kambayashi et al., 2009; Wang et al., 
2007). In each case, expression of MHC 
class II is low compared to mature den-
dritic cells and is more compatible with a 
role for these cells in augmenting inflam-
mation through interactions with effector 
Th2 cells in peripheral tissues rather than 
in priming naive T cells in lymph nodes, 
where activation thresholds are greater. 
Indeed, activation of naive T cells to 
gain IL-4 competence is IL-4 indepen-
dent during priming in lymph nodes (van 
Panhuys et al., 2008), but entry into and/
or maturation of Th2 cells in tissues is 
highly Stat6 dependent, suggesting the 
need for exogenous IL-4 in mediating 
localization, maturation, and/or activa-
tion of Th2 cells in affected tissues rather 
than in lymph node priming. Here, imag-
ing studies would allow more compelling 
evidence that basophils, as compared to 
dendritic cells, can mediate efficient acti-
vation of naive T cells in lymph nodes. 
Accurate lineage marking of basophils 
has not been accomplished and remains 
a pressing need. Regardless, the conflu-
ence of the recent studies requires fur-
ther investigation, including extension to 
humans, in order not to overlook findings 
of fundamental importance. Contribu-
tions of other IL-13-producing cells, such 
as incompletely characterized IL-25R+ 
lymphoid cells in lung and intestinal tis-
sues, need to be examined, particularly 
in humans, as targeting IL-25, a potent 
activator of these cells, has substantial 
benefits in animal models of allergic lung 
inflammation (Ballantyne et al., 2007).
The absence of efficient imaging 
modalities has stymied efforts to more 
accurately assess components of aller-
gic inflammation in the lung and draining 
lymph nodes. The lung presents a com-
plex highly branched tissue optimized 
for gas exchange but offering a large 
mucosal surface for antigen surveillance. 
A heterogeneous group of lung dendritic 
cells and macrophages patrol epithelia 
from the large conducting airways to the 
alveolae, and the balance of tolerance-
inducing and stimulatory responses is 
only beginning to be unraveled (Lam-
brecht and Hammad, 2009). The precise 
flow of soluble allergens such as pro-
teases or particulates like chitin from con-
ducting airways to the mediastinal lymph 
nodes is not well studied, although ana-
tomic studies in rodents suggest precise 
partitioning of materials ferried from the 
lung to draining lymph nodes. Although 
not without limitations, thick sections of 
agarose-inflated lung can be maintained 
in oxygenated media for up to 5 days 
and offer an approach yet to be fully 
explored for live imaging (Delmotte and 
Sanderson, 2006). Fluorescent molecu-
lar tomography (FMT) uses protease-
sensitive probes to detect inflammation 
by transillumination in living animals. The 
depth of penetration and scale of reso-
lution allow reconstructive analysis of 
three-dimensional tissues, including the 
lung. The pathogenic role of proteases in 
asthma and allergy suggests that FMT 
can be utilized with cell lineage markers 
to more accurately study the organiza-
tion of the inflammatory milieu in the lung 
(Cortez-Retamozo et al., 2008). Com-
puterized tomographic imaging is being 
paired with functional studies using 
inhaled hyperpolarized 3He magnetic 
resonance imaging to investigate more 
completely the mechanisms driving air-
way collapse and airspace trapping that 
underlies the ventilation heterogeneity in 
asthma. Although thick-walled airways 
and lumenal narrowing are evident, more 
surprising is the extended time required 
for recovery of ventilatory abnormalities 
after allergen challenge in asthmatic as 
compared to non-asthmatic individuals, 
and the finding that ventilation defects 
in a given subject tend to be fixed in the 
same areas with repeated studies over 
time, suggesting an irreversible structural 
component to the process (de Lange et 
al., 2009; Tzeng et al., 2009). Asthma has 
complex effects on the lung due to the 
interconnections between intrinsic tis-
sue and conducting airway mechanics 
and the functional consequences of air-
space collapse on both. Further efforts 
linking the physical and immunological 
realms are needed.
The Big Picture
Despite the presence of homologs and 
paralogs in flies and other insects that 
reveal vestiges of immunity against bac-
teria, fungi, and viruses mediated by 
macrophage-like phagocytic cells, simi-
lar evolutionary evidence for the origins 
of allergic immunity is not obvious. The 
increasingly complex nutrient needs of 
larger organisms with prolonged partu-
rition have been linked with expanded 
mucosal surfaces required for tissue 
oxygenation and caloric uptake. The 
latter has driven a symbiotic develop-
mental relationship with a highly diverse 
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microbial commensal flora intimately 
involved in optimizing nutrient extrac-
tion and mucosal immune homeostasis 
that has no exact counterpart in inver-
tebrates (Backhed et al., 2005; Round 
and Mazmanian, 2009) (see Review by 
W.S. Garrett et al. in this issue). The 
constituents of the bacterial flora and 
their contributions to human health are 
being increasingly defined, but it is likely 
that additional intestinal resident organ-
isms—namely, parasitic helminths—also 
drove mutualism in the mucosa. In natu-
ral environments worldwide, the great 
majority of vertebrates are infected with 
intestinal helminths, including humans 
in rural environments where exposure 
to contaminated soils and water is high. 
Oetzi the Iceman, a mummified indi-
vidual over 50 centuries old found in the 
Alps of Europe, was infected with whip-
worm (Aspock et al., 1996). Parasitic 
helminths include nematodes (round-
worms, such as hookworms and whip-
worms) and platyhelminths (flatworms, 
including flukes and tapeworms) and 
afflict billions of people in developing 
countries. The diversity in natural envi-
ronments is astounding (Parkinson et al., 
2004). Nematodes alone have been esti-
mated to make up 80% of all animals on 
the earth and comprise possibly a mil-
lion species. Among the five nematode 
clades, all include parasitic species of 
plants and animals.
In experimental studies, the response 
to helminths shares many attributes with 
asthma and allergic inflammation, includ-
ing requirements for IL-4 and IL-13, the 
presence of eosinophil-rich inflamma-
tory infiltrates, elevated IgE, alterations in 
smooth muscle contractility, goblet cell 
hyperplasia, and mucus production, and 
increased epithelial cell turnover, all of 
which are felt to underlie the “weep and 
sweep” response to intestinal infestation. 
Helminths secrete an array of proteases 
and lipid-binding proteins and express 
chitin in eggs and the cuticular pharynx. 
Despite the inclination to associate aller-
gic inflammation with host immunity to 
helminths, it is still not clear whether hel-
minths have coevolved with the immune 
response to fashion a niche in which to 
establish a symbiotic relationship in the 
nutrient-rich intestine. Examples have 
been noted in which helminths exploit 
eosinophilia for infection, induce alter-
native macrophage activation, and elicit 
cytokines, such as TSLP and IL-25, that 
mitigate mucosal injury and moderate 
Treg development in involved tissues 
(Maizels et al., 2009). In healthy Ugan-
dans, eosinophilia is the single most 
common laboratory “abnormality” as 
based on Western hematologic reference 
values and contributes to the difficulty in 
conducting vaccine trials against HIV and 
other pathogens due to exclusion criteria 
(Eller et al., 2008). It is more likely, however, 
that eosinophilia and increased numbers 
of tissue basophils and mast cells were 
“normal” hematologic responses during 
human evolution and represent homeo-
static responses induced to maintain 
healthy tissues in the face of universal 
intestinal parasitism. Inflammatory dis-
eases such as asthma, but also obesity, 
metabolic syndrome, and atherosclerosis 
(see Review by G.S. Hotamisligil in this 
issue), have increased in areas where 
intestinal parasitism has decreased. Fur-
ther investigations are needed to assess 
whether the symbiosis of early humans 
with intestinal helminths as compared 
to the widespread absence in urban-
ized humans today has led to significant 
modifications in the microbial commen-
sal flora, changes in the availability of 
micronutrients such as vitamins A and 
D involved in mucosal immune homeo-
stasis, or even alterations in the kinetics 
of the development of the mucosal lym-
phoid system. Early alterations of air-
way microbial flora have been noted in 
infants at later risk for asthma (Bisgaard 
et al., 2007). Such speculation has been 
advanced previously as a component of 
the “hygiene hypothesis” (Yazdanbakhsh 
et al., 2002). Further study of the impact of 
intestinal parasitism on mucosal bacterial 
commensals and immune homeostasis in 
humans might prove fruitful in attempting 
to understand the increasing prevalence 
of allergic diseases among humans in a 
modern world (Figure 2). Obesity, itself 
a contributor to asthma severity, may 
also result from alterations in pathways 
impacting the human microbiota (Blaser 
and Falkow, 2009). Until better insights 
regarding the nature and function of 
allergic immunity are known, tempered 
caution is offered that we should not 
eliminate all facets of these responses, 
otherwise basic homeostatic pathways 
may be inadvertently compromised.
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